Disease · MONDO_0006096

atypical endometrial hyperplasia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. atypical endometrial hyperplasia. Diseases, record MONDO_0006096. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006096

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: atypical endometrial hyperplasia; Open Targets
Open Targets ID: MONDO_0006096; Open Targets
Other names: atypical hyperplasia of endometrium, atypical hyperplasia of the endometrium, endometrial hyperplasia with atypia; Open Targets
NCI Thesaurus: C4654; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 16 drugs, from DailyMed; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PROGESTERONE	CHEMBL103	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
MEDROXYPROGESTERONE ACETATE	CHEMBL717	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DYDROGESTERONE	CHEMBL1200853	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MEGESTROL ACETATE	CHEMBL1201139	Small molecule	Phase 2/3	ClinicalTrials.gov	13	13	13	Drugs and targets
LEVONORGESTREL	CHEMBL1389	Small molecule	Phase 2/3	ClinicalTrials.gov	9	9	9	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 2/3	ClinicalTrials.gov	4	4	4	Drugs and targets
GONADORELIN	CHEMBL1007	Protein	Phase 2/3	ClinicalTrials.gov	3	3	0	Drugs and targets
GONADORELIN ACETATE	CHEMBL1200511	Protein	Phase 2/3	ClinicalTrials.gov	3	3	0	Drugs and targets
ROSUVASTATIN	CHEMBL1496	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets57

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PGR	Progesterone receptor	6	Progesterone receptor agonist	Approval	https://conductscience.org/library/genes/5241	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	3	HMG-CoA reductase inhibitor	Phase 2/3	https://conductscience.org/library/genes/3156	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	2	Glucagon-like peptide 1 receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2740	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	2	Gonadotropin-releasing hormone receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2798	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2/3	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2/3	https://conductscience.org/library/genes/56901	Drugs and targets
CYP19A1	Aromatase	1	Cytochrome P450 19A1 inhibitor	Phase 2/3	https://conductscience.org/library/genes/1588	Drugs and targets
GIPR	Gastric inhibitory polypeptide receptor	1	Gastric inhibitory polypeptide receptor agonist	Phase 2	https://conductscience.org/library/genes/2696	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 2/3	https://conductscience.org/library/genes/2820	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2/3	https://conductscience.org/library/genes/4535	Drugs and targets

1 to 10 of 57

See all 57 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01968317	Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma	Phase 2	150	2021-09-13	Endometrial Atypical Hyperplasia, Endometrial Adenocarcinoma	MEGESTROL ACETATE, METFORMIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00483327	Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate	Phase 2	31	2016-07-01	Atypical Endometrial Hyperplasia, Endometrial Carcinoma	MEGESTROL ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00503581	Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia	Phase 2	9	2020-10-14	High Grade Squamous Intraepithelial Neoplasia, Stage 0 Uterine Corpus Cancer	MEGESTROL ACETATE	Its record names the disease	ClinicalTrials.gov
NCT03675139	MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia	Phase 3	471		Endometrial Hyperplasia Without Atypia	DYDROGESTERONE, MEDROXYPROGESTERONE ACETATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03463252	Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC	Phase 2/3	224		Endometrial Cancer, Atypical Endometrial Hyperplasia	LEVONORGESTREL, PROGESTERONE	Its record names the disease	ClinicalTrials.gov
NCT03241888	Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia	Phase 2/3	180		Atypical Endometrial Hyperplasia	LEVONORGESTREL, MEGESTROL ACETATE	Its record names the disease	ClinicalTrials.gov
NCT05316493	Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia	Phase 2/3	172		Atypical Endometrial Hyperplasia, Fertility Issues, Overweight and Obesity	LEVONORGESTREL, MEGESTROL ACETATE	Its record names the disease	ClinicalTrials.gov
NCT01686126	Improving the Treatment for Women With Early Stage Cancer of the Uterus	Phase 2	165		Complex Endometrial Hyperplasia With Atypia, Grade 1 Endometrial Endometrioid Adenocarcinoma	LEVONORGESTREL, METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT04385667	LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia	Phase 2/3	143		Atypical Endometrial Hyperplasia	LEVONORGESTREL, MEGESTROL ACETATE	Its record names the disease	ClinicalTrials.gov
NCT07436793	Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial	Phase 2	140		Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia	MEGESTROL ACETATE, PROGESTERONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Megestrol Acetate and Metformin vs Megestrol Acetate: deaths from any cause	0 of 76	0 of 74	150	NCT01968317	Trial comparisons
Megestrol Acetate and Metformin vs Megestrol Acetate: serious adverse events	0 of 76	0 of 74	150	NCT01968317	Trial comparisons
Megestrol Acetate and Metformin vs Megestrol Acetate: Cumulative CR Rates Within 32 Weeks	52 of 70	45 of 66	136	NCT01968317	Trial comparisons
Megestrol Acetate and Metformin vs Megestrol Acetate: Recurrence Rate	7 of 69	6 of 66	135	NCT01968317	Trial comparisons
Megestrol Acetate and Metformin vs Megestrol Acetate: Cumulative CR Rates Within 16 Weeks	23 of 67	12 of 58	125	NCT01968317	Trial comparisons
Megestrol Acetate and Metformin vs Megestrol Acetate: Pregnancy Rate	19 of 37	15 of 31	68	NCT01968317	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41286566	DERIVED	1	PubMed
39215793	DERIVED	1	PubMed
38425141	DERIVED	1	PubMed
37182434	DERIVED	1	PubMed
33762086	DERIVED	1	PubMed
32909630	DERIVED	2	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006096

GET https://conductscience.org/api/diseases/v1/MONDO_0006096/targets?page=2

API reference For AI assistants